Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Cresco Labs (CRLBF) Amortization of Deferred Charges (2020 - 2025)

Historic Amortization of Deferred Charges for Cresco Labs (CRLBF) over the last 6 years, with Q3 2025 value amounting to $517000.0.

  • Cresco Labs' Amortization of Deferred Charges fell 5900.08% to $517000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $4.6 million, marking a year-over-year decrease of 415.45%. This contributed to the annual value of $4.9 million for FY2024, which is 994.11% up from last year.
  • Cresco Labs' Amortization of Deferred Charges amounted to $517000.0 in Q3 2025, which was down 5900.08% from $1.7 million recorded in Q2 2025.
  • Over the past 5 years, Cresco Labs' Amortization of Deferred Charges peaked at $7.4 million during Q3 2021, and registered a low of $517000.0 during Q3 2025.
  • Its 5-year average for Amortization of Deferred Charges is $1.5 million, with a median of $1.2 million in 2024.
  • Per our database at Business Quant, Cresco Labs' Amortization of Deferred Charges surged by 6009.02% in 2021 and then crashed by 8635.2% in 2022.
  • Over the past 5 years, Cresco Labs' Amortization of Deferred Charges (Quarter) stood at $7.4 million in 2021, then tumbled by 86.35% to $1.0 million in 2022, then grew by 14.97% to $1.2 million in 2023, then rose by 3.53% to $1.2 million in 2024, then plummeted by 56.95% to $517000.0 in 2025.
  • Its Amortization of Deferred Charges stands at $517000.0 for Q3 2025, versus $1.7 million for Q2 2025 and $1.2 million for Q1 2025.